Skip to main content

Table 1 Effects of alemtuzumab on lineage differentiation during ex vivo expansion of CB stem cells

From: Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells

Cell Surface Markers

Expression Level

 

Control Cultures

Cultures with alemtuzumab

 

Percentage ± SD

Absolute Cell Count (× 105)

Percentage ± SD

Absolute Cell Count (× 105)

CD52

8.63 ± 2.49

1.32 ± 0.44

0.10 ± 0.08

0.02 ± 0.02

CD90

3.58 ± 1.46

0.55 ± 0.24

0.10 ± 0.03

0.02 ± 0.01

CD14

23.01 ± 3.73

3.53 ± 0.80

17.71 ± 3.18

3.70 ± 0.84

Glycophorin-A

0.57 ± 0.33

0.09 ± 0.05

0.71 ± 0.48

0.15 ± 0.10

CD13

84.86 ± 4.27

13.01 ± 2.18

89.85 ± 1.88

18.78 ± 2.63

CD41

19.82 ± 1.12

3.04 ± 0.52

22.63 ± 1.32

4.73 ± 0.71

  1. Phenotype of day-14 ex vivo expansion cultures: Liquid cultures for 14 day ex vivo expansion were established with 100,000 CD34+ cells in 50 ng/ml of SCF, TPO and Flt-3 Ligand. The results of six separate experiments are expressed in terms of different surface marker expression levels on day 14.